INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRATED BIOPHARMA INC revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing [Member] | $42.39M | $46.49M | $50.13M | $50.88M | $51.68M | $50.43M | $49.72M | $49.10M | $48.57M | $48.68M | $48.52M | $49.15M | 96.6% | -18.0% |
| Other Nutraceutical Business [Member] | $1.48M | $1.76M | $1.97M | $2.55M | $2.67M | $2.49M | $2.40M | $1.92M | $1.75M | $1.89M | $1.99M | $2.11M | 3.4% | -44.4% |
By product or service
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $35.23M | $38.73M | $41.29M | $42.85M | $43.63M | $42.43M | $42.88M | $42.47M | $42.34M | $43.84M | $43.58M | $44.07M | 80.3% | -19.2% |
| Non-US [Member] | $8.64M | $9.56M | $10.80M | $10.58M | $10.73M | $10.50M | $9.25M | $8.55M | $7.97M | $6.72M | $6.93M | $7.19M | 19.7% | -19.4% |
From the segment and revenue-disaggregation notes of Integrated Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.